Bosch Healthcare Solutions GmbH
Near-patient PCR rapid test for whooping cough for Vivalytic by Bosch now available / World's first fully automated PCR test for detection of B. pertussis, B. parapertussis, B. holmesii
more
Stories about Impfung
Therapeutic Vaccine for Chronic Hepatitis B Enters Clinical Trial
moreLTS Lohmann Therapie-Systeme AG
LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches
moreTechnische Universität München
Vaccination campaign messages often prove ineffective
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center phone: +49 89 289 22798 - email: presse@tum.de - web: www.tum.de NEWS RELEASE Vaccination campaign messages often prove ineffective Study in eight countries demonstrates barriers for communications on Covid-19 Conventional vaccination campaign messages often miss their targets. A study in eight European countries shows that information on the benefits of ...
moreQ-VANT and In vitro Plant-tech Sign Agreement for the Development and Supply of Quillaja saponaria Plant Cell Culture Biomass
BOSTON, MA (ots) - --News Direct-- Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed an agreement with In vitro Plant-tech AB, a Swedish plant cell cultivation company whose ...
moreALDER HEY AND NEEDLESMART PARTNERSHIP AIMS TO REDUCE 100,000 NEEDLESTICK INJURIES TO NHS HEALTHCARE WORKERS
moreTechnische Universität München
A medication against SARS-CoV-2 – new strategy also promises protection against future SARS-CoV-2 variants
TECHNICAL UNIVERSITY OF MUNICHCorporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/en/about-tum/news/press-releases/details/37076 High resolution images: https://mediatum.ub.tum.de/1637268 NEWS RELEASE A medication against ...
more- 2
R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation
more - 2
German MECOTEC Group delivers 8 containers for deep-freeze storage of Covid-Vaccines
more Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
Freiburg (ots) - Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates. Its recently expanded production ...
more- 6
Press Release MAHLE Covid-19 worldwide vaccination initiatives
more Technische Universität München
New approach identifies T cells in Covid-19 patients
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36882/ NEWS RELEASE New approach identifies T cells in Covid-19 patients Immune cell profile reveals appearance, number and activity level against SARS-CoV-2 T cells play a decisive role in fighting the ...
moreTechnische Universität München
The virus trap: hollow nano-objects made of DNA could trap viruses and render them harmless
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36810/ High resolution images: https://mediatum.ub.tum.de/1616943 NEWS RELEASE The virus trap Hollow ...
moreTechnische Universität München
Versatile, fast and reliable: new automated microarray rapid test detects SARS-CoV-2 antibodies
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36762/ High resolution images: https://mediatum.ub.tum.de/1615381 NEWS RELEASE Versatile, fast and reliable SARS-CoV-2 antibody assay Automated microarray ...
moreDid my vaccine work? New rapid test for the determination of vaccination success
moreFirst pocket inhaler for Covid-19 and other viral mutations
Buochs (ots) - DG-Nika AG – a new approach to therapy & proactive protection from the pandemic The corona pandemic continues to pose a global threat: To date, it has been possible to vaccinate only a small fraction of the total population. On top of that, there is acute danger from mutations of this virus. Against this backdrop, the DG-Nika AG research team has developed a solution for a new approach to protecting the ...
moreHellmann provides Germany-wide distribution of COVID-19 vaccines for the government
morenal von minden plans to produce 80 million rapid corona tests per month
more- 2
German MECOTEC Group launches one-stop-solution for deep-freeze, transport, storage and distribution for COVID-19-Vaccines with its first Mobile Hybrid Container
more Swiss Rockets AG announces the founding of ROCKETVAX for the development of a next-generation SARS-CoV-2 vaccine
moreTechnische Universität München
Immune response: memory T cells are formed earlier than previously thought
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22562 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36297/ NEWS RELEASE How the immune system remembers viruses Immune response: memory T cells are formed earlier than previously thought For a person to ...
moreNew: Combined rapid test for Covid-19 and influenza
moreIgNova files patent application on antibody against COVID-19
Visbek, Germany (ots) - IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (IgY). The patented IgY binds the spike protein of SARS-CoV-2, neutralizing the virus when it enters the mouth or nose and, therefore, inhibiting the ...
moreNew in-vivo study confirms that ciliate vaccine protects against flu
more
1